Factors influencing engraftment in HLA-haploidentical/mismatch related transplantation with combined granulocyte-colony stimulating factor-mobilized peripheral blood and bone marrow for patients with leukemia

Transfusion and Apheresis Science

Volumn 44, Issue 3, 2011, Pages 249-255

  Zhang, Cheng ^a   Zhang, Xi ^a   Chen, Xing Hua ^a   Gao, Li ^a   Gao, Lei ^a   Kong, Pei Yan ^a   Peng, Xian Gui ^a   Sun, Ai Hua ^a   Wang, Qing Yu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Engraftment; Granulocyte colony stimulating factor; Hematologic malignancies; HLA haploidentical mismatch related transplantation; Leukemia

Indexed keywords

ACICLOVIR; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACLIZUMAB; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; LOMUSTINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SULFAMETHOXAZOLE; TACROLIMUS; THYMOCYTE ANTIBODY; TRIMETHOPRIM;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD; BONE MARROW; CELL; CHILD; CHRONIC MYELOID LEUKEMIA; ENGRAFTMENT; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; INFANT; INFECTION; INFECTION PREVENTION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NEUTROPHIL COUNT; PNEUMOCYSTOSIS; PRESCHOOL CHILD; SCHOOL CHILD; STEM CELL; STEM CELL TRANSPLANTATION; THROMBOCYTE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGE FACTORS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HLA ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 79958767765     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2011.04.005     Document Type: Article

References (40)

1. Koh L.P., Chao N.J. Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review. Blood Cells Mol Dis 2008, 40(1):20-24.
2. Chen X., Zhang C., Zhang X., et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009, 15(2):266-273.
3. Bishop M.R., Henslee-Downey P.J., Anderson J.R., et al. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. Bone Marrow Transplant 1996, 18(4):747-753.
4. Schattenberg A.V., Dolstra H. Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Curr Opin Oncol 2005, 17(6):617-621.
5. Tricot G., Jagannath S., Vesole D., et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995, 85(2):588-596.
6. Stockerl-Goldstein K.E., Reddy S.A., Horning S.F., et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with " poor" mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000, 6(5):506-512.
7. Takeyama K., Ohto H. PBSC mobilization. Transfus Apher Sci 2004, 31(3):233-243.
8. Zhang C., Chen X.H., Zhang X., et al. Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings. Transfus Med 2010, 20(3):169-177.
9. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
10. Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110(7):2764-2767.
11. Aggarwal S., Pittinger M.F. Human mesenchymal stem cells modulate alloantigen immune cell responses. Blood 2005, 105(4):1815-1822.
12. Tatsumi K., Otani H., Sato D., et al. Granulocyte-colony stimulating factor increases donor mesenchymal stem cells in bone marrow and their mobilization into peripheral circulation but does not repair dystrophic heart after bone marrow transplantation. Circul J 2008, 72(8):1351-1358.
13. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004, 104(4):961-968.
14. Zhang C., Chen X., Zhang X., et al. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematologic malignancies: influence of disease, mobilization method, age and sex. Transfus Apher Sci 2008, 39(1):21-28.
15. Wang T.F., Wen S.H., Chen R.L., et al. Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. Biol Blood Marrow Transplant 2008, 14(11):1305-1311.
16. Aversa F., Reisner Y., Martelli M.F. The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2008, 40(1):8-12.
17. Passweg J.R. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Prac Res Clin Haematol 2006, 19(4):811-824.
18. Huang X.J., Chang Y.J., Zhao X.Y. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transplant Immunol 2007, 17(3):193-197.
19. Lu D.P., Dong L.J., Wu T., et al. Conditioning including antithymocyte HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107(8):3065-3073.
20. Huang X.J., Han W., Xu L.P., et al. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Chin Med J 2004, 117(12):1778-1785.
21. Dong L., Wu T., Zhang M.J., et al. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant 2007, 13(12):1515-1524.
22. Mohty M., Bilger K., Jourdan E., et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003, 17(8):869-875.
23. Lang P., Bader P., Schumm M., et al. Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol 2004, 124(1):72-79.
24. Bethge W.A., Haegele M., Faul C., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol 2006, 34(12):1746-1752.
25. Luo X.H., Chang Y.J., Xu L.P., et al. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant 2009, 43(1):29-36.
26. Morton J., Hutchins C., Durrant S. Granulocyte colonystimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001, 98(12):3186-3191.
27. Jansen E.M., Hanks S.G., Terry C., et al. Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?. Transfusion 2007, 47(5):817-823.
28. Singhal S., Powles R., Treleaven J., et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2×10(6) CD34+ cells/kg be considered the minimum threshold?. Bone Marrow Transplant 2000, 26(5):489-496.
29. Chang Y.J., Xu L.P., Liu D.H., et al. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. Biol Blood Marrow Transplant 2009, 15(5):9632-9638.
30. Helbig G., Stella-Holowiecka B., Wojnar J., et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor derived erythropoiesis after long-term treatment using different therapeutic strategies. Ann Hematol 2007, 86(9):677-683.
31. Zhu K.E., Li J.P., Zhang T., et al. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematology 2007, 12(2):117-121.
32. Yazer M.H., Triulzi D.J. Immune hemolysis following ABO mismatched stem cell or solid organ transplantation. Curr Opin Hematol 2007, 14(6):664-670.
33. Kanda J., Ichinohe T., Matsuo K., et al. Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion 2009, 49(4):624-635.
34. Bader P., Willasch A., Niethammer D., et al. Haploidentical stem cell transplantation in childhood. Curr Cancer Ther Rev 2007, 3(1):37-44.
35. van Rood J.J., Loberiza F.R., Zhang M.J., et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002, 99(5):1572-1577.
36. Ichinohe T., Uchiyama T., Shimazaki C., et al. Feasibility of HLA haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 2004, 104(12):3821-3828.
37. Stussi G., Muntwyler J., Passweg J.R., et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 30(2):87-93.
38. Chang Y.J., Xu L.P., Liu D.H., et al. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. Biol Blood Marrow Transplant 2009, 15(5):632-638.
39. Chen X.H., Zhang C., Zhang X., et al. Cost and outcome in stem cells collection on HLA-haploidentical/mismatched related transplantation with combined granulocyte colony stimulating factor mobilized blood and bone marrow for patients with hematologic malignancies. Transfus Apher Sci 2010, 43(1):23-28.
40. Chen X.H., Gao L., Zhang X., et al. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation. Blood Cells Mol Dis 2009, 43(1):98-104.